Skip to content

Study · Case report or series · n = 1 · 2020

3 results

Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report.

Terakawa A, Chujo D, Yasuda K, Ueno K, Nakamura T, Hamano S, Ohsugi M, Tanabe A, Ueki K, Kajio H

Medicine1 Aug 2020Cited by 13 (Europe PMC)

PMID32871938 (opens in a new tab)PMCIDPMC7458169 (opens in a new tab)DOI10.1097/md.0000000000021939 (opens in a new tab)PepBankPUB-32871938
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

RationaleMaturity-onset diabetes of the young type 5 (MODY 5) is a form of monogenic diabetes that is often accompanied by pancreatic dysfunction. To date, no cases of MODY 5 treated with glucagon-like peptide-1 receptor agonist (GLP-1RA) have been reported. We present the first case of MODY 5 treated with GLP-1RA.Patient concernsA 17-year-old woman, with a history of being operated for congenital ileal atresia at birth, was admitted to our hospital due to hyperglycemia. She had been clinically diagnosed with type 1 diabetes 1 month prior, and administered 14 units of insulin glargine 300 U/mL per day.DiagnosisShe had hypopotassemia, hypomagnesaemia, pancreatic body, and tail defects, multiple renal cysts, and a family history of diabetes, and urogenital anomaly. Genetic testing revealed heterozygous deletion of hepatocyte nuclear transcription factor-1 beta, leading to the diagnosis of MODY 5.InterventionsThe patient was treated with multiple daily insulin injections for 9 days (22 units/d) before administration of GLP-1RA, and then liraglutide was initiated.OutcomesLiraglutide treatment (0.6 mg/d) alone maintained the patient's glycated hemoglobin level below 7.0% for at least 12 months after discharge. A higher dose, 0.9 mg/d, of liraglutide was not tolerated by the patient due to nausea. Serum levels of C-peptide immunoreactivity were 1.15 ng/mL and 1.91 ng/mL, respectively, after 6 and 12 months of liraglutide therapy.LessonsGLP-1RA might be effective at regulating glucose metabolism by utilizing residual pancreatic endocrine function in patients with MODY 5. Imaging and genetic screening were helpful in the diagnosis of MODY 5.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 17-year-old woman with MODY 5, liraglutide 0.6 mg/d alone maintained glycated hemoglobin below 7.0% for at least 12 months after discharge.

    In plain wordsIn one young woman with a rare form of diabetes (MODY 5), liraglutide alone kept HbA1c below 7.0% for at least 12 months.

    Peptide
    Liraglutide
    Outcome
    Not applicableHbA1c maintained below 7.0 percent
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.6 mg/d · at least 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Liraglutide treatment (0.6 mg/d) alone maintained the patient's glycated hemoglobin level below 7.0% for at least 12 months after discharge.
    1 context sentence
    Summary · context
    A 17-year-old woman, with a history of being operated for congenital ileal atresia at birth, was admitted to our hospital due to hyperglycemia.
  2. 02HumanCase report or seriesSafety outcome

    In a 17-year-old woman with MODY 5, liraglutide 0.9 mg/d was not tolerated because of nausea.

    In plain wordsIn one young woman with MODY 5, a higher liraglutide dose caused nausea and she could not tolerate it.

    Peptide
    Liraglutide
    Outcome
    Not applicableNausea at liraglutide 0.9 mg/d
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.9 mg/dAs given in this study (human).

    Source sentences

    Summary
    A higher dose, 0.9 mg/d, of liraglutide was not tolerated by the patient due to nausea.
    1 context sentence
    Summary · context
    A 17-year-old woman, with a history of being operated for congenital ileal atresia at birth, was admitted to our hospital due to hyperglycemia.
  3. 03HumanCase report or seriesEfficacy outcome

    In a 17-year-old woman with MODY 5, serum C-peptide immunoreactivity was 1.15 ng/mL after 6 months and 1.91 ng/mL after 12 months of liraglutide therapy.

    In plain wordsIn one young woman with MODY 5, blood C-peptide, a sign of insulin production, was measured at 6 and 12 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableSerum C-peptide immunoreactivity
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Serum C-peptide immunoreactivity
    1.15 ng/mL
    after 6 months of liraglutide
    Serum C-peptide immunoreactivity
    1.91 ng/mL
    after 12 months of liraglutide

    Source sentences

    Summary
    Serum levels of C-peptide immunoreactivity were 1.15 ng/mL and 1.91 ng/mL, respectively, after 6 and 12 months of liraglutide therapy.
    1 context sentence
    Summary · context
    A 17-year-old woman, with a history of being operated for congenital ileal atresia at birth, was admitted to our hospital due to hyperglycemia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.